TCGA-XF-A8HE-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 125.3942181
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- G2M_CHECKPOINT+0.540
- INTERFERON_GAMMA_RESPONSE+0.530
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.490
- INFLAMMATORY_RESPONSE+0.450
- MTORC1_SIGNALING+0.440
- MYC_TARGETS_V1+0.440
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.400
Top 10 suppressed
- MYOGENESIS-0.230
- BILE_ACID_METABOLISM-0.150
- PEROXISOME-0.140
- TGF_BETA_SIGNALING-0.130
- UV_RESPONSE_DN-0.100
- NOTCH_SIGNALING-0.090
- PANCREAS_BETA_CELLS-0.090
- ESTROGEN_RESPONSE_EARLY-0.080
- XENOBIOTIC_METABOLISM-0.080
- PROTEIN_SECRETION-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20080189.TNBC | — | E | 0.915 |
| 2 | BSR_16_0031_E2_S98 | — | C | 0.898 |
| 3 | SRR35579821 | — | E | 0.886 |
| 4 | MNG766 | — | — | 0.873 |
| 5 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.873 |
| 6 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.866 |
| 7 | TCGA-G2-A2ES-01A-11R-A180-07 | — | — | 0.855 |
| 8 | TCGA-BH-A1F6-01A-11R-A13Q-07 | — | E | 0.855 |
| 9 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.855 |
| 10 | TCGA-A8-A07U-01A-11R-A034-07 | — | D | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |